Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ILK | Q13418 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15423021 | 0.78 | HTR2B (0.64) | HTR2BTRPM8HSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL31069423 | 0.78 | HTR2B (0.64) | HTR2BTRPM8 | |
| SCHEMBL24919879 | 0.78 | HTR2B (0.64) | HTR2BTRPM8 | |
| SCHEMBL13462337 | 0.77 | HTR2B (0.63) | HTR2BTRPM8CDC7DBF4RAB9A | |
| SCHEMBL12469453 | 0.74 | HTR2B (0.58) | HTR2BTRPM8SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL12469388 | 0.73 | HTR2B (0.57) | HTR2BTRPM8KDM4EHPGDHSD17B10 | |
| SCHEMBL15423062 | 0.71 | HTR2B (0.55) | HTR2BTRPM8KDM4EHSD17B10SMN1; SMN2 | |
| SCHEMBL9313715 | 0.70 | HTR2B (0.53) | HTR2BTRPM8KDM4EHPGDHSD17B10 | |
| SCHEMBL28485399 | 0.70 | HTR2B (0.53) | HTR2BTRPM8KDM4EHPGDHSD17B10 | |
| SCHEMBL18003834 | 0.70 | HTR2B (0.54) | HTR2BKDM4EHPGDALDH1A1CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751847-B2 | Methods and compositions related to neuroactive thiazoline compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751847-B2 | Methods and compositions related to neuroactive thiazoline compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751847-B2 | Methods and compositions related to neuroactive thiazoline compounds | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-09-05 | — | — | US | disclosed |
| US-20140018400-A1 | METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018400-A1 | METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018400-A1 | METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018400-A1 | METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS | TACR2, TACR3, TACR1 | HTR2B 58/4885TRPM8 161/4885KDM4E 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.